Rifabutin for infusion (BV100) for the treatment of severe carbapenem-resistant Acinetobacter baumannii infections

Autor: Glenn E. Dale, Marc Gitzinger, Vincent Trebosc, Christian Kemmer, Sergio Lociuro

Publikováno v: Drug discovery today. 26(9)

Rifamycin antibiotics were discovered during the 1950s, and their main representative, rifampicin, remains a cornerstone treatment for TB. The clinical use of rifamycin is restricted to mycobacteria and Gram-positive infections because of its poor ab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70c866cb51941543cdc6cc18e059c53e
https://pubmed.ncbi.nlm.nih.gov/34242796

Murepavadin: a new antibiotic class in the pipeline

Autor: Glenn E. Dale, Antoni Torres, Ignacio Martin-Loeches

Publikováno v: Expert Review of Anti-infective Therapy. 16:259-268

With the increase in multi-drug resistant P. aeruginosa, antimicrobials with a novel mechanism of action are needed that can target these infections. Areas covered: Intravenous murepavadin is in Phase 3 development for the treatment of HABP/VABP due

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fd2b2814d2978aaf66e28a4ad3c457f
https://doi.org/10.1080/14787210.2018.1441024

Chimeric peptidomimetic antibiotics against Gram-negative bacteria

Autor: Sarah Stiegeler, Caroline Kolopp, Alessandra Vitale, Maik Müller, Anatol Luther, Sophie Hell, Nicolas Desjonquères, Annie Vermeulen, Gregory Upert, Michel Schmitt, Petra Chiquet, Leo Eberl, Elizabeth Cline, Seyed Majed Modaresi, Virginie Rithié, Parthasarathi Rath, Fabio Lo Monte, Glenn E. Dale, Francesca Bernardini, Jean-Baptiste Hartmann, Marie-Anne Westwood, Achim Wach, Alexander Lederer, Régis Jaisson, Sebastian Hiller, Karen LePoupon, Daniel Obrecht, Hans H. Locher, Shuang-Yan Wang, John A. Robinson, Bernd Wollscheid, Milon Mondal, Carolin Verbree, Emile Brabet, Timothy Sharpe, Matthias Urfer, Gabriella Pessi, Peter Zbinden, Katja Zerbe, Harsha Kocherla, Tobias Remus, Michael Zahn, Kerstin Moehle

There is an urgent need for new antibiotics against Gram-negative pathogens that are resistant to carbapenem and third-generation cephalosporins, against which antibiotics of last resort have lost most of their efficacy. Here we describe a class of s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59ac561055e1f885369d402e6179d3b6
https://www.zora.uzh.ch/id/eprint/184028/

Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models

Autor: J. Teague, P. Warn, Daniel Obrecht, Glenn E. Dale, J. Hansen, Maria J. Melchers, Johan W. Mouton, Achim Wach, Francesca Bernardini

Publikováno v: Antimicrobial Agents and Chemotherapy, 63, 3
Antimicrobial Agents & Chemotherapy, 63(3):e01699-18. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 63

Murepavadin (POL7080) represents the first member of a novel class of outer membrane protein-targeting antibiotics. It specifically interacts with LptD and inhibits lipopolysaccharide (LPS) transport. Murepavadin is being developed for the treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43629d4812bf79e88242ee847340e1c2
https://hdl.handle.net/2066/202109

Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China

Autor: Glenn E. Dale, Helio S. Sader, Robert K. Flamm, Paul R. Rhomberg

Publikováno v: Antimicrobial agents and chemotherapy. 62(7)

Murepavadin (formerly POL7080), a 14-amino-acid cyclic peptide, and comparators were tested by the broth microdilution method against 1,219 Pseudomonas aeruginosa isolates from 112 medical centers. Murepavadin (MIC 50/90 , 0.12/0.12 mg/liter) was 4-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3333bcbb079d8e0cec9c581d57b1ded
https://pubmed.ncbi.nlm.nih.gov/29686157